ROCKVILLE, Md., Oct 30 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 third quarter financial results in a press release to be issued after 8:00 am local time on Friday, November 6, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. local time on Friday, November 6, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 814-8448 (International: 1 (703) 639-1367.
A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning November 6, 2009 at 1:00 pm through November 8, 2009 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter pass code 1394584.
About Novavax, Inc.
Novavax, Inc. is a clinical-stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The Company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com
SOURCE Novavax, Inc.
|SOURCE Novavax, Inc.|
Copyright©2009 PR Newswire.
All rights reserved